SCHEMBL1604847

SCHEMBL1604847

NCCCNc1ncnc2sc3c(c12)CCCC3

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.67
CSNK2B P67870 1/20 0.67
CSNK2A1 P68400 1/20 0.67
MEN1 O00255 1/20 0.63
PTGS2 P35354 2/20 0.62
ALDH1A1 P00352 3/20 0.61
MAPT P10636 3/20 0.61
GAA P10253 2/20 0.61
KDM4E B2RXH2 1/20 0.61
LMNA P02545 4/20 0.60
TSHR P16473 3/20 0.60
PDE5A O76074 1/20 0.60
HPGD P15428 1/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GFER P55789 1/20 0.58
REN P00797 1/20 0.57
LIMK1 P53667 2/20 0.55
MKNK1 Q9BUB5 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL540857 0.85 CSNK2A2 (0.64) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL13164911 0.84 CSNK2A2 (0.73) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL13164925 0.84 CSNK2A2 (0.63) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL19523723 0.82 ALDH1A1 (0.62) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL759362 0.81 LMNA (0.63) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL13164903 0.80 CSNK2A2 (1.00) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL13164910 0.79 LMNA (0.86) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL13164894 0.79 MAPT (0.84) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL12375203 0.79 MAPT (0.94) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2
SCHEMBL13164898 0.79 MEN1 (0.98) CSNK2A2CSNK2BCSNK2A1MEN1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 EP disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
EP-1797099-B1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2010-08-11 EP disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
EP-1797099-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS Epix Delaware, Inc. (US) 2007-06-20 EP disclosed
WO-2006034511-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE, INC. (US) 2006-03-30 WO disclosed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 US disclosed
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR5A, HTR3A, HTR1A CSNK2A2 2789/4885CSNK2B 2708/4885CSNK2A1 2579/4885
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds HTR2B, HTR3B, HTR1B CSNK2A2 3502/4885CSNK2B 2967/4885CSNK2A1 3793/4885
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR2B, HTR3B, HTR1B CSNK2A2 3502/4885CSNK2B 2967/4885CSNK2A1 3793/4885
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds HTR5A, HTR3A, HTR1A CSNK2A2 3203/4885CSNK2B 3167/4885CSNK2A1 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.